Insight Molecular Diagnostics Inc. (IMDX)
NASDAQ: IMDX · Real-Time Price · USD
6.09
+0.21 (3.57%)
At close: May 22, 2026, 4:00 PM EDT
6.15
+0.06 (0.92%)
After-hours: May 22, 2026, 4:10 PM EDT
IMDX Revenue
Insight Molecular Diagnostics had revenue of $32.00K in the quarter ending March 31, 2026, a decrease of -98.50%. This brings the company's revenue in the last twelve months to $1.95M, down -49.28% year-over-year. In the year 2025, Insight Molecular Diagnostics had annual revenue of $4.06M with 115.58% growth.
Revenue (ttm)
$1.95M
Revenue Growth
-49.28%
P/S Ratio
100.89
Revenue / Employee
$33,603
Employees
58
Market Cap
196.63M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.06M | 2.17M | 115.58% |
| Dec 31, 2024 | 1.88M | 378.00K | 25.15% |
| Dec 31, 2023 | 1.50M | 545.00K | 56.89% |
| Dec 31, 2022 | 958.00K | -1.24M | -56.41% |
| Dec 31, 2021 | 2.20M | 982.00K | 80.76% |
| Dec 31, 2020 | 1.22M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
| FONAR | 105.34M |
| Biodesix | 96.10M |
| Prenetics Global | 92.39M |
| Burning Rock Biotech | 77.14M |
| Exagen | 68.38M |
IMDX News
- 10 days ago - Insight Molecular Diagnostics Earnings Call Transcript: Q1 2026 - Transcripts
- 10 days ago - Insight Molecular Diagnostics Earnings release: Q1 2026 - Filings
- 10 days ago - Insight Molecular Diagnostics Shareholder letter: Q1 2026 - Filings
- 10 days ago - Insight Molecular Diagnostics Quarterly report: Q1 2026 - Filings
- 10 days ago - IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - GlobeNewsWire
- 10 days ago - Insight Molecular Diagnostics Slides: Investor presentation - Filings
- 17 days ago - iMDx to Release First Quarter 2026 Results on May 13, 2026 - GlobeNewsWire
- 23 days ago - Insight Molecular Diagnostics Proxy statement: Proxy filing - Filings